Novartis Acquires Option to Phase II siRNA Drug from Quark Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 8 (Table of Contents)
Published: 13 Oct-2010
DOI: 10.3833/pdr.v2010.i8.1383 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Quark Pharmaceuticals has granted Novartis an option to license QPI-1002, a drug for acute kidney injury that is currently in Phase II, in a deal that could be worth US$670 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS